BioSpectrum India ’s Post

New Publication: Improving Fertility in Non-Obstructive Azoospermia I'm thrilled to announce the publication of our article, "Improving Fertility in Non-Obstructive Azoospermia: Results from An Autologous Bone Marrow-Derived Mesenchymal Stromal/Stem Cell Phase I Clinical Trial," in the International Journal of Fertility and Sterility in 2024. I had the privilege of collaborating with an incredible research team to bring this important work to life. Huge thanks to all the co-authors for their contributions! Summary: This Phase I clinical trial aimed to explore a novel treatment for non-obstructive azoospermia (NOA) using autologous bone marrow-derived mesenchymal stromal/stem cells (BM-MSCs). The trial involved 80 participants, comparing BM-MSC transplantation with hormone therapy. Results showed significant improvements in hormonal profiles, sperm concentration, and the regeneration of seminiferous tubules, with 22.5% of patients experiencing successful fertility outcomes. Our findings highlight the potential of BM-MSCs as a safe and effective treatment for NOA. #FertilityResearch #StemCellTherapy #ClinicalTrial #Azoospermia #MedicalInnovation #BMMSC #ResearchCollaboration

The US endometriosis start-up Hera Biotech has reached an agreement to acquire the endometriosis diagnostic assets and associated IP of single-cell and biomarker discovery company Scailyte. https://lnkd.in/eumubfCm Somer Baburek, MBA Peter Nestorov Cinzia Donato Nameer Kirma Paul Castella #endometriosis #endometriosisawareness #womenshealth #fertility #infertility #fertilityjourney #fertilityawareness #reproductivehealth #health #healthandwellbeing #tech #healthtech #femtech #biotech #research #innovation #healthinnovation #diagnostics #diagnosis #acquisition #business #startup #texas #news #healthnews #businessnews

"We are excited to work with Hera to integrate Scailyte’s endometriosis assets into the Hera pipeline. Through our collaboration with Prof. Michael Mueller from the University of Bern, we have generated the largest single-cell RNAseq datasets from peripheral blood and endometrial tissue. The insights we gained clearly indicate that the tissue-based approach is the only way to capture the complexity and heterogeneity of endometriosis, and therefore tissue-based molecular assays will be the only viable alternative to laparoscopy for a definitive diagnosis and patient stratification." Scailyte CEO Dr. Peter Nestorov Somer Baburek, MBA Hera Biotech #femtech #womenshealth #womenshealthinnovation #endometriosis #pelvichealth #fertility #reproductivehealth #infertility #diagnostics #health #healthcare #biotech

𝗜𝗩𝗙 - 𝗦𝘆𝗿𝗶𝗻𝗴𝗲𝘀 𝗠𝗮𝗿𝗸𝗲𝘁 𝟮𝟬𝟮𝟰-𝟮𝟬𝟯𝟮. 𝗚𝗹𝗼𝗯𝗮𝗹 𝗥𝗲𝘀𝗲𝗮𝗿𝗰𝗵 𝗥𝗲𝗽𝗼𝗿𝘁 The clinical application of in vitro fertilization (IVF) extends to both preimplantation genetic diagnosis (PGD) and addressing infertility. Nowadays, IVF techniques have evolved to encompass genetic disorders such as Huntington's disease, cancer predisposition, and Alzheimer’s disease. Stem cells obtained from umbilical cord blood from unaffected siblings originating from embryos are transferred to patients, also utilized in preserving fertility for cancer patients. The growing awareness of IVF procedures, coupled with advancements in existing technologies, is projected to drive the expansion of the IVF syringes market. The report provides insights into the development of the IVF syringes industry chain, assessing the market status in hospitals and fertility clinics, including intramuscular and subcutaneous injections. It delves into key enterprises in developed and developing markets, analyzing cutting-edge technology, patents, hot applications, and market trends. Regionally, North America and Europe are experiencing steady growth propelled by government initiatives and increasing consumer awareness, while Asia-Pacific, particularly China, leads the global IVF syringes market due to robust domestic demand, supportive policies, and a strong manufacturing base. 𝗧𝗼 𝗞𝗻𝗼𝘄 𝗚𝗹𝗼𝗯𝗮𝗹 𝗦𝗰𝗼𝗽𝗲 𝗮𝗻𝗱 𝗗𝗲𝗺𝗮𝗻𝗱 𝗼𝗳 𝗜𝗩𝗙 - 𝗦𝘆𝗿𝗶𝗻𝗴𝗲𝘀 𝗠𝗮𝗿𝗸𝗲𝘁. 𝗥𝗲𝗾𝘂𝗲𝘀𝘁 𝗳𝗼𝗿 𝗦𝗮𝗺𝗽𝗹𝗲 𝗣𝗗𝗙: https://lnkd.in/dgTEUt4Z *𝗕𝘆 𝗧𝘆𝗽𝗲: Intramuscular Injection, Subcutaneous Injection *𝗕𝘆 𝗔𝗽𝗽𝗹𝗶𝗰𝗮𝘁𝗶𝗼𝗻: Hospitals, Fertility Clinics, Others *𝗕𝘆 𝗥𝗲𝗴𝗶𝗼𝗻: North America, Europe, Asia-Pacific, South America, Middle East & Africa *𝗕𝘆 𝗞𝗲𝘆 𝗣𝗹𝗮𝘆𝗲𝗿𝘀: Thermo Fisher Scientific,  Vitrolife,  Cook Medical,  CooperSurgical,  Hunter Scientific Limited #ivf #syringes #fertilitytreatment #reproductivehealth #medicaldevices #healthcare #invitrofertilization #fertilitysolutions #assistedreproduction #infertility #reproductivemedicine #ivftreatment #ivfsuccess #medicaltechnology #healthtech #biotechnology #healthcareindustry #patientcare #innovation #marketanalysis #medicalresearch #healthcareproviders

"This study is the first to demonstrate the end-to-end process by which a therapy developed from induced pluripotent stem cells (iPSC) has the potential to enhance in vitro fertilization (IVF) outcomes and advance women's health, paving the way for its application in clinical settings." Dr. Dina Radenkovic, CEO and Co-founder of Gameto Christian Kramme, PhD #femtech #fertility #infertility #ttc #biotech #ivf #ivfclinic #art #reproductivehealth #health #healthcareinnovation #clinicalresearch #clinicalstudy #research #regulatory #startup #scaleup

Nearly 20 million new cases of cancer are being diagnosed per year but with the advent of improved treatment modalities for patients being diagnosed with Cancer the survival rates have increased drastically. About 7% of women of reproductive age are diagnosed with cancer annually, thus Infertility becomes a very important cancer survivorship issue and is associated with depression and diminished quality of life. I was invited to deliver a lecture on " Does Cancer itself affect Fertility?" Organised by Fertility Preservation Society India ( FPSI) and Dr Vyjayanthi, KIMS, Hyderabad #Cancer #infertility #Fertility #Reproductiveage #radiotherapy #chemotherapy #Oocyte #cryopreservation #sperm #testiculartissue #ovariantissue #Preservation #fertilitypreservation #embryo #treatment

We're excited to share groundbreaking insights from our latest research on the blog: "The Efficacy of Personalized Immunotherapy on Embryo Implantation: Insights from a Retrospective Study." This comprehensive analysis dives into how personalized immunotherapy is setting a new benchmark in fertility treatments, offering hope to those facing challenges in conceiving. Our study, inspired by the pioneering work of Lédée, meticulously evaluates the impact of personalized immunotherapy across patients with specific immune dysregulations. With a focus on enhancing embryo implantation rates, our findings not only shed light on the potential of targeted immunomodulatory strategies but also pave the way for a more individualized approach in fertility medicine. Key highlights: A detailed exploration of patient outcomes based on their endometrial immune profiles. Significant improvement in implantation rates with tailored immunotherapy for patients with identified immune dysregulations. A call for precision in patient selection and the critical role of endometrial immune profiling in crafting personalized treatment plans. Join us in exploring how this study marks a significant leap towards personalized fertility treatment and the promising future it heralds. For an in-depth understanding of our methodology, findings, and the transformative implications of our work, click through to read the full article. Read More ⏭️ https://bit.ly/3TsTHpg #FertilityTreatment #PersonalizedMedicine #Immunotherapy #AssistedReproductiveTechnology #InnovationInHealthcare

OXOLIFE founders participate in a new publication, giving perspectives about What 2024 holds for Biopharma in the Women's Health therapeutic area. Along with other experts in the field (Jessica J. Federer, Colby Holtshouse, Laura Gault, David Solomon), we draw a positive future with greater investment opportunities to restore years of lack of research on women's needs and reverse the current dearth of innovations focused on women   Find our contribution ⬇⬇ and the whole publication at https://bit.ly/49wXQiy.     "It's time for a billion-dollar reproductive health fund," declared Agnès Arbat, CEO and chief medical officer of Oxolife, which is developing a drug to enhance embryo implantation. "Recognizing the urgency, women's health has achieved impressive momentum in recent times. New initiatives are emerging to foster innovation and address unmet medical needs, like the first-ever White House initiative on women's health research launched in November 2023. New treatments are poised to contribute to transformative change during 2024, such as the expectation that significant progress will be made in enhancing embryo implantation, the main cause today of ART [assisted reproductive technology] failure. Late-stage clinical developments are advancing in this area and pioneering approaches are expected to be announced, playing a pivotal role in reshaping the future of fertility in the years to come."   Ignasi Canals Almazán, chief scientific officer, said: "In the realm of women's health and fertility, innovation has been under-represented in R&D relative to the burden. Despite making up more than half of the population, women's health has been chronically underserved. The femtech sector is estimated to be worth $1tn by 2027, but the 'taboo’ nature of women’s health and gender imbalances in investment are providing obstacles to the industry. Contrary to other fields, the regulatory path is underexplored, with no established endpoints and biomarkers, or accelerated tracks for approval. Consequently, women’s health has been flooded with a lot of early clinical or non-clinical ideas but there is a scarcity of innovations among products in late-stage development.”  

𝗦𝘁𝗲𝗺 𝗖𝗲𝗹𝗹 𝗧𝗵𝗲𝗿𝗮𝗽𝘆 𝗳𝗼𝗿 𝗣𝗿𝗲𝗺𝗮𝘁𝘂𝗿𝗲 𝗢𝘃𝗮𝗿𝗶𝗮𝗻 𝗙𝗮𝗶𝗹𝘂𝗿𝗲 𝗠𝗮𝗿𝗸𝗲𝘁 𝟮𝟬𝟮𝟰-𝟮𝟬𝟯𝟰. 𝗚𝗹𝗼𝗯𝗮𝗹 𝗥𝗲𝘀𝗲𝗮𝗿𝗰𝗵 𝗥𝗲𝗽𝗼𝗿𝘁 𝗥𝗲𝗾𝘂𝗲𝘀𝘁 𝗳𝗼𝗿 𝗦𝗮𝗺𝗽𝗹𝗲: https://lnkd.in/dWY2t63t Premature ovarian failure (POF), also known as primary ovarian insufficiency or early menopause, is a prevalent gynecological endocrine disorder where women under 40 experience loss of ovarian function, often leading to irreversible infertility. This report offers an in-depth analysis of the global market for stem cell therapy targeting POF, presenting both quantitative and qualitative insights by company, region, country, type, and application. As the market evolves, the report examines competitive dynamics, supply and demand trends, and key factors driving changes in various markets. It also includes company profiles, product examples from selected competitors, and market share estimates of leading companies for 2024. *𝗕𝘆 𝗧𝘆𝗽𝗲: Mesenchymal Stem Cells, Extra-embryonic Stem Cells, Others *𝗕𝘆 𝗔𝗽𝗽𝗹𝗶𝗰𝗮𝘁𝗶𝗼𝗻: Less than 20 Years Old, 20 to 30 Years Old, 30 to 45 Years Old, 45 Years Old and Older *𝗕𝘆 𝗥𝗲𝗴𝗶𝗼𝗻: North America, Europe, Asia-Pacific, South America, Middle East & Africa #StemCellTherapy #PrematureOvarianFailure #POFTreatment #OvarianHealth #PrimaryOvarianInsufficiency #EarlyMenopause #FertilityTreatment #ReproductiveHealth #WomenHealth #StemCellResearch #OvarianRegeneration #FertilitySolutions #InnovativeTherapies #EndocrineDisorders #InfertilitySupport #CellTherapy #RegenerativeMedicine #GynecologicalHealth #FertilityCare #FutureOfFertility